361 related articles for article (PubMed ID: 32326161)
1. Cystic Fibrosis, CFTR, and Colorectal Cancer.
Scott P; Anderson K; Singhania M; Cormier R
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326161
[TBL] [Abstract][Full Text] [Related]
2. Defective CFTR promotes intestinal proliferation via inhibition of the hedgehog pathway during cystic fibrosis.
Liu K; Wang X; Zou C; Zhang J; Chen H; Tsang L; Yu MK; Chung YW; Wang J; Dai Y; Liu Y; Zhang X
Cancer Lett; 2019 Apr; 446():15-24. PubMed ID: 30639531
[TBL] [Abstract][Full Text] [Related]
3. CFTR is a tumor suppressor gene in murine and human intestinal cancer.
Than BL; Linnekamp JF; Starr TK; Largaespada DA; Rod A; Zhang Y; Bruner V; Abrahante J; Schumann A; Luczak T; Walter J; Niemczyk A; O'Sullivan MG; Medema JP; Fijneman RJ; Meijer GA; Van den Broek E; Hodges CA; Scott PM; Vermeulen L; Cormier RT
Oncogene; 2016 Aug; 35(32):4179-87. PubMed ID: 26751771
[TBL] [Abstract][Full Text] [Related]
4.
Kim K; Lane EA; Saftien A; Wang H; Xu Y; Wirtz-Peitz F; Perrimon N
Proc Natl Acad Sci U S A; 2020 May; 117(19):10357-10367. PubMed ID: 32345720
[TBL] [Abstract][Full Text] [Related]
5. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis.
Karb DB; Cummings LC
Curr Gastroenterol Rep; 2021 Aug; 23(10):17. PubMed ID: 34448955
[TBL] [Abstract][Full Text] [Related]
6. The risk of colorectal cancer in individuals with mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene: An English population-based study.
Birch RJ; Peckham D; Wood HM; Quirke P; Konstant-Hambling R; Brownlee K; Cosgriff R; Consortium GER; Burr N; Downing A
J Cyst Fibros; 2023 May; 22(3):499-504. PubMed ID: 36253274
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles.
Terlizzi V; Castaldo G; Salvatore D; Lucarelli M; Raia V; Angioni A; Carnovale V; Cirilli N; Casciaro R; Colombo C; Di Lullo AM; Elce A; Iacotucci P; Comegna M; Scorza M; Lucidi V; Perfetti A; Cimino R; Quattrucci S; Seia M; Sofia VM; Zarrilli F; Amato F
J Med Genet; 2017 Apr; 54(4):224-235. PubMed ID: 27738188
[TBL] [Abstract][Full Text] [Related]
8. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
[TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis mouse model-dependent intestinal structure and gut microbiome.
Bazett M; Honeyman L; Stefanov AN; Pope CE; Hoffman LR; Haston CK
Mamm Genome; 2015 Jun; 26(5-6):222-34. PubMed ID: 25721416
[TBL] [Abstract][Full Text] [Related]
10. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
Derichs N
Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
[TBL] [Abstract][Full Text] [Related]
11. Association of IVS6A GATT polymorphism of CFTR gene with cystic fibrosis: first study in CF and normal Tunisian population.
Chaima S; Sondess HF; Khedija B; Ahmed M; Taieb M
Ann Biol Clin (Paris); 2020 Jun; 78(3):314-318. PubMed ID: 32540817
[TBL] [Abstract][Full Text] [Related]
12. The proteome speciation of an immortalized cystic fibrosis cell line: New perspectives on the pathophysiology of the disease.
Puglia M; Landi C; Gagliardi A; Breslin L; Armini A; Brunetti J; Pini A; Bianchi L; Bini L
J Proteomics; 2018 Jan; 170():28-42. PubMed ID: 28970102
[TBL] [Abstract][Full Text] [Related]
13. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.
Persu A; Devuyst O; Lannoy N; Materne R; Brosnahan G; Gabow PA; Pirson Y; Verellen-Dumoulin C
J Am Soc Nephrol; 2000 Dec; 11(12):2285-2296. PubMed ID: 11095651
[TBL] [Abstract][Full Text] [Related]
14. Genotype and phenotype in cystic fibrosis.
Zielenski J
Respiration; 2000; 67(2):117-33. PubMed ID: 10773783
[TBL] [Abstract][Full Text] [Related]
15. CFTR dysregulation drives active selection of the gut microbiome.
Meeker SM; Mears KS; Sangwan N; Brittnacher MJ; Weiss EJ; Treuting PM; Tolley N; Pope CE; Hager KR; Vo AT; Paik J; Frevert CW; Hayden HS; Hoffman LR; Miller SI; Hajjar AM
PLoS Pathog; 2020 Jan; 16(1):e1008251. PubMed ID: 31961914
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous spectrum of mutations in CFTR gene from Indian patients with congenital absence of the vas deferens and their association with cystic fibrosis genetic modifiers.
Sharma H; Mavuduru RS; Singh SK; Prasad R
Mol Hum Reprod; 2014 Sep; 20(9):827-35. PubMed ID: 24958810
[TBL] [Abstract][Full Text] [Related]
17. Fecal dysbiosis and inflammation in intestinal-specific Cftr knockout mice on regimens preventing intestinal obstruction.
Young SM; Woode RA; Williams EC; Ericsson AC; Clarke LL
Physiol Genomics; 2024 Mar; 56(3):247-264. PubMed ID: 38073491
[TBL] [Abstract][Full Text] [Related]
18. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
19. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
20. Islet-intrinsic effects of CFTR mutation.
Koivula FNM; McClenaghan NH; Harper AGS; Kelly C
Diabetologia; 2016 Jul; 59(7):1350-1355. PubMed ID: 27033560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
